GeoVax Labs (NASDAQ:GOVX) Posts Quarterly Earnings Results, Beats Expectations By $15.60 EPS

GeoVax Labs (NASDAQ:GOVX) issued its earnings results on Thursday. The company reported ($10.56) EPS for the quarter, beating the consensus estimate of ($26.16) by $15.60, FiscalAI reports.

GeoVax Labs Price Performance

Shares of GOVX stock traded down $0.12 during trading hours on Thursday, hitting $2.04. 125,927 shares of the company’s stock were exchanged, compared to its average volume of 42,020. The stock’s 50-day moving average is $6.91 and its 200-day moving average is $27.58. The stock has a market cap of $632,400.00, a price-to-earnings ratio of -0.18 and a beta of 3.85. GeoVax Labs has a 52 week low of $1.84 and a 52 week high of $300.00.

Wall Street Analyst Weigh In

A number of equities analysts have commented on GOVX shares. Weiss Ratings restated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Thursday, October 15th. Noble Financial reaffirmed an “outperform” rating on shares of GeoVax Labs in a report on Tuesday, September 15th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, GeoVax Labs has a consensus rating of “Hold” and an average target price of $3,600.00.

About GeoVax Labs

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer. The company’s technology platform is based primarily on modified vaccinia Ankara (MVA) and virus-like particle (VLP) vaccine technologies, which are designed to generate broad and durable immune responses. GeoVax’s pipeline has included GEO-CM04S1, a multivalent COVID-19 vaccine candidate intended to address emerging coronavirus variants, as well as investigational vaccines for HIV, hemorrhagic fever viruses such as Ebola and Marburg, and other infectious diseases.